Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
This trial is conducted in Africa, Asia, Europe, North and South America. The aim of the trial is to compare the effect of once-weekly (OW) dosing of subcutaneous semaglutide (1.0 mg) versus once-daily dosing of oral canagliflozin (300 mg) on glycaemic control in subjects with type 2 diabetes (T2D) on a background treatment of metformin
Epistemonikos ID: 37032dbc1003863a4ffd5d278ac6a539375131b3
First added on: May 28, 2024